News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News NICE approval for Keytruda a 'milestone' in lung cancer But drug will not be funded for longer than two years.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
